Article

C677T methylenetetrahydrofolate reductase gene polymorphisms in bipolar disorder: an association study in the Chinese population and a meta-analysis of genetic association studies.

Institute for Nutritional Science, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Tai Yuan Road, Shanghai 200031, China.
Neuroscience Letters (impact factor: 2.11). 11/2008; 449(1):48-51. DOI:10.1016/j.neulet.2008.10.077 pp.48-51
Source: PubMed

ABSTRACT The methylenetetrahydrofolate reductase (MTHFR) gene variant C677T is suspected to be a risk factor for psychiatric disorders, but it remains uncertain whether the MTHFR C677T variant is associated with bipolar disorders. To investigate possible association, unrelated controls (n=461) with no history of psychiatric disorders and patients (n=501) diagnosed with bipolar disorder were recruited in this study. In addition, six association studies published up to June 2008 were included in a subsequent meta-analysis. No significant difference was found in either allele frequencies or genotype distribution between patients and controls in our association study in the Chinese population. Similarly, the meta-analysis result showed no significant association between MTHFR C677T and bipolar disorder. In conclusion, the MTHFR C677T variant is unlikely to play a major role in the susceptibility to bipolar disorder, although MTHFR plays an important role in the one-carbon metabolism and DNA methylation.

0 0
 · 
0 Bookmarks
 · 
29 Views
  • Article: Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope.
    [show abstract] [hide abstract]
    ABSTRACT: No specific gene has been identified for any major psychiatric disorder, including schizophrenia, in spite of strong evidence supporting a genetic basis for these complex and devastating disorders. There are several likely reasons for this failure, ranging from poor study design with low statistical power to genetic mechanisms such as polygenic inheritance, epigenetic interactions, and pleiotropy. Most study designs currently in use are inadequate to uncover these mechanisms. However, to date, genetic studies have provided some valuable insight into the causes and potential therapies for psychiatric disorders. There is a growing body of evidence suggesting that the understanding of the genetic etiology of psychiatric illnesses, including schizophrenia, will be more successful with integrative approaches considering both genetic and epigenetic factors. For example, several genes including those encoding dopamine receptors (DRD2, DRD3, and DRD4), serotonin receptor 2A (HTR2A) and catechol-O-methyltransferase (COMT) have been implicated in the etiology of schizophrenia and related disorders through meta-analyses and large, multicenter studies. There is also growing evidence for the role of DRD1, NMDA receptor genes (GRIN1, GRIN2A, GRIN2B), brain-derived neurotrophic factor (BDNF), and dopamine transporter (SLC6A3) in both schizophrenia and bipolar disorder. Recent studies have indicated that epigenetic modification of reelin (RELN), BDNF, and the DRD2 promoters confer susceptibility to clinical psychiatric conditions. Pharmacologic therapy of psychiatric disorders will likely be more effective once the molecular pathogenesis is known. For example, the hypoactive alleles of DRD2 and the hyperactive alleles of COMT, which degrade the dopamine in the synaptic cleft, are associated with schizophrenia. It is likely that insufficient dopaminergic transmission in the frontal lobe plays a role in the development of negative symptoms associated with this disorder. Antipsychotic therapies with a partial dopamine D2 receptor agonist effect may be a plausible alternative to current therapies, and would be effective in symptom reduction in psychotic individuals. It is also possible that therapies employing dopamine D1/D2 receptor agonists or COMT inhibitors will be beneficial for patients with negative symptoms in schizophrenia and bipolar disorder. The complex etiology of schizophrenia, and other psychiatric disorders, warrants the consideration of both genetic and epigenetic systems and the careful design of experiments to illumine the genetic mechanisms conferring liability for these disorders and the benefit of existing and new therapies.
    American Journal of PharmacoGenomics 02/2005; 5(3):149-60.
  • Article: Family, twin, adoption, and molecular genetic studies of juvenile bipolar disorder.
    [show abstract] [hide abstract]
    ABSTRACT: Juvenile bipolar disorder (JBD) has been a subject of significant research and debate. Phenotypic differences between JBD and adult-onset bipolar disorder have led researchers to question whether or not similar neuropathologic mechanisms will be found. While much is known about the genetic and environmental contributions to the adult-onset phenotype, less is known about their contributions to JBD. Here, we review family, twin, adoption, and molecular genetic studies of JBD. Behavioral genetic data suggest both genetic and environmental contributions to JBD, while molecular genetic studies find linkage to age of onset of bipolar disorder to chromosomes 12p, 14q, and 15q. Additionally, changes associated with symptom age of onset have been recently reported in the brain-derived neurotrophic factor (BDNF) and glycogen synthase kinase 3-beta (GSK3-beta) genes. We contend that further progress in discovering the precise genetic and environmental contributions to JBD may depend on advances in phenotypic refinement, an increased appreciation of comorbid conditions, and more investigation of the longitudinal course of the disorder.
    Bipolar Disorders 01/2006; 7(6):598-609. · 5.29 Impact Factor
  • Article: Diagnostic issues in bipolar disorder.
    [show abstract] [hide abstract]
    ABSTRACT: Bipolar disorder is a highly recurrent and chronic psychiatric condition that shortens life expectancy, causes functional impairment and disruption to social, work and family life. Several forms of bipolar disorder are recognised, including both bipolar I and bipolar II disorder. Bipolar I is characterised by recurrent episodes of depression and mania whereas bipolar II disorder is characterised by recurrent depression and hypomania, a milder form of mania. There has been debate concerning the definition of hypomania since at least the 1970s. The main areas of argument focus on the minimum duration of hypomania, its stem criteria and the number of symptoms required for diagnosis. Arriving at the correct definition of hypomania is a key diagnostic issue. There is increasing evidence for the existence of a broad spectrum of bipolar disorders, and data demonstrating the clinical validity of modifying some of the criteria for hypomania are reviewed here.
    European Neuropsychopharmacology 09/2003; 13 Suppl 2:S43-50. · 4.05 Impact Factor

Full-text

View
7 Downloads
Available from
30 Nov 2012

Keywords

allele frequencies
 
association studies
 
association study
 
bipolar disorder
 
bipolar disorders
 
Chinese population
 
DNA methylation
 
meta-analysis result
 
methylenetetrahydrofolate reductase
 
MTHFR
 
MTHFR C677T variant
 
one-carbon metabolism
 
patients
 
possible association
 
psychiatric disorders
 
risk factor
 
significant association
 
subsequent meta-analysis
 
susceptibility
 
unrelated controls